Related Experiment Videos
Rifampin reduces early mortality in experimental Streptococcus pneumoniae meningitis
1Neurologische Universitätsklinik, D-37075 Göttingen, Germany. rnau@gwdg.de
Abstract:
Compared with beta-lactam antibiotics, rifampin releases smaller quantities of proinflammatory cell wall products from Streptococcus pneumoniae in vitro. Mice infected intracerebrally with S. pneumoniae were treated subcutaneously with 2-mg doses of rifampin or ceftriaxone (n=43 each) every 12 h for 3 days and then observed for another 3 days. Rifampin reduced overall mortality from 49% to 26% (P=.04). Kaplan-Meyer analysis revealed a substantial reduction of mortality during the first 24 h in mice receiving rifampin (difference in survival time: P=.007). Eight h after receiving a single 2-mg dose of rifampin or ceftriaxone, rifampin-treated mice had lower serum and cerebrospinal fluid concentrations of lipoteichoic and teichoic acids than did ceftriaxone-treated mice (median serum level: <0.5 vs. 27.0 ng/mL, P=.02; median cerebrospinal fluid level of pooled specimens: 97.5 vs. 206.0 ng/mL). Thus, the use of rifampin appears promising for reducing the release of proinflammatory bacterial components and decreasing early mortality in bacterial meningitis.
Insights
Rifampin significantly reduced mortality in mice with Streptococcus pneumoniae meningitis compared to ceftriaxone. This antibiotic also lowered proinflammatory bacterial components, suggesting a promising role in treating bacterial meningitis.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Bacterial meningitis remains a critical condition with high mortality rates.
- Proinflammatory bacterial components released during treatment can exacerbate meningitis.
- Beta-lactam antibiotics are standard but may increase the release of these components.
Purpose of the Study:
- To compare the efficacy of rifampin and ceftriaxone in a murine model of Streptococcus pneumoniae meningitis.
- To evaluate the impact of rifampin on the release of proinflammatory bacterial cell wall products.
Main Methods:
- Intracerebral Streptococcus pneumoniae infection in mice.
- Subcutaneous treatment with rifampin or ceftriaxone (2-mg doses every 12h for 3 days).
- Mortality assessment and measurement of serum and cerebrospinal fluid lipoteichoic and teichoic acids.
Main Results:
- Rifampin reduced overall mortality from 49% to 26% (P=.04).
- Rifampin significantly decreased early mortality within the first 24 hours (P=.007).
- Rifampin-treated mice showed lower serum and CSF concentrations of lipoteichoic and teichoic acids.
Conclusions:
- Rifampin demonstrates a promising therapeutic effect in reducing mortality associated with bacterial meningitis.
- Rifampin's ability to limit the release of proinflammatory bacterial components may contribute to its improved outcomes.
- Further investigation into rifampin for bacterial meningitis treatment is warranted.